2076-P: Time Restricted Eating (TRE) Promotes Weight Loss, Alters Body Composition, and Improves Metabolic Parameters in Overweight Humans

Abstract

TRE, restriction of the eating window, reduces weight in animals and humans. We performed a randomized clinical trial examining the effect of TRE on body composition and glycemic measures in overweight humans without diabetes. We hypothesized that TRE will reduce weight and alter body composition compared with unrestricted feeding (non-TRE). 21 overweight subjects [18F/3M, mean(SE), age: 44.7 years (2.7), BMI:34.6 kg/m2(1.7) with a prolonged eating window:15.6 hours (0.2)] were randomized to either 12 weeks of TRE [n=11 (goal 8 hours)] or non-TRE [n=10]. All oral intake was logged using the myCircadianClock smart phone application to remotely monitor TRE adherence. Subjects also underwent: 2-hour oral glucose tolerance test, 2-week continuous glucose monitoring (Freestyle Libre), and 2-week activity tracking (Actigraph Link) pre and post intervention. Compared with the non-TRE group [eating window 15.2 hours (0.3)] post-intervention, the TRE group [eating window 10.4 hours (0.6)] decreased weight [-3.6 kg(0.6) vs. -1.4 kg(0.7)], visceral fat [-260 g(110) vs. 38 g(56)], lean mass [-1450 g(389) vs. -95.5 g(351)] and triglycerides [-23.6%(6.8) vs. -0.57%(7.6)] (all p≤0.05). Relative to baseline, the TRE group decreased: weight, fasting glucose, fat mass, lean mass, visceral fat, and fasting triglyceride levels (all p<0.05). This was not observed in the non-TRE group. TRE-related weight loss was associated with lower: fat mass [-4%(0.9)], visceral fat [-11%(4.0)], and lean mass [-3%(0.8)] relative to baseline (all p<0.05). All TRE-related effects were not significant after adjusting for weight loss. Neither intervention significantly altered physical activity. In overweight subjects, TRE reduced weight and improved metabolic parameters (triglycerides, fasting glucose). However, the TRE-related weight loss included both lean and fat mass loss. Further investigation into the translational aspects of TRE to treat obesity-related disorders is warranted. Disclosure L.S. Chow: Research Support; Self; Eli Lilly and Company. E. Manoogian: None. A.C. Alvear: None. Q. Wang: None. S. Panda: Other Relationship; Self; PenguinRandomHouse. D.G. Mashek: Consultant; Self; Eli Lilly and Company. Research Support; Self; Eli Lilly and Company. Funding University of Minnesota Healthy Foods Healthy Lives (17SFR-2YR50LC)